Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria A randomized, double-blind, placebo-controlled, phase ii trial

Sadayoshi Ito, Kenichi Shikata, Masaomi Nangaku, Yasuyuki Okuda, Tomoko Sawanobori

Research output: Contribution to journalArticle

Abstract

Background and objectives The progression of kidney disease in some patients with type 2 diabetes mellitus may not be adequately suppressed by renin-angiotensin system inhibitors. Esaxerenone (CS-3150) is a nonsteroidalmineralocorticoid receptor blocker that has shown kidney protective effects in preclinical studies, and it is apotential add-ontherapyto treatdiabetic kidney disease.Thisphase 2 studyevaluatedthe efficacy andsafetyof esaxerenone in Japanese patients with type 2 diabetes mellitus and microalbuminuria. Design, setting, participants, & measurements This multicenter, randomized, double-blind, placebo-controlled trial enrolled 365 hypertensive or normotensive patients with type 2 diabetes mellitus and microalbuminuria (urinary albumin-to-creatinine ratio ≥45 to <300 mg/g creatinine) treated with renin-angiotensin system inhibitor who had eGFR≥30 ml/min per 1.73 m2. Participants were randomized to receive 0.625, 1.25, 2.5, or 5 mg/d esaxerenone or placebo for 12 weeks. The primary end point was the change in urinary albumin-tocreatinine ratio from baseline to week 12 (with last observation carried forward). Results Esaxerenone treatment at 1.25, 2.5, and 5mg/d significantly reduced urinary albumin-to-creatinine ratio by the end of treatment (38%, 50%, and 56%, respectively) compared with placebo (7%; all P<0.001). The urinary albumin-to-creatinine ratio remission rate (defined as urinary albumin-to-creatinine ratio <30mg/g creatinine at the end of treatment and ≥30% decrease from baseline) was 21% in the 2.5- and 5-mg/d groups versus 3% for placebo (both P<0.05). Adverse events occurred slightly more frequently with esaxerenone versus placebo, but the frequencies of drug-related adverse events and discontinuation rates were similar in the placebo and the 0.625-, 1.25-, and 2.5-mg/d groups.Drug-related adverse events and treatment discontinuationsweremarginally higher in the 5-mg/d group. The most common drug-related adverse event was hyperkalemia, which was dose proportional. Conclusions Adding esaxerenone at 1.25, 2.5, and 5 mg/d for 12 weeks to an ongoing renin-angiotensin system inhibitor significantly reduces urinary albumin-to-creatinine ratio in patients with type 2 diabetes mellitus and microalbuminuria.

Original languageEnglish
Pages (from-to)1161-1172
Number of pages12
JournalClinical Journal of the American Society of Nephrology
Volume14
Issue number8
DOIs
Publication statusPublished - Aug 7 2019

Fingerprint

Type 2 Diabetes Mellitus
Creatinine
Placebos
Albumins
Safety
Renin-Angiotensin System
Drug-Related Side Effects and Adverse Reactions
Kidney Diseases
Therapeutics
Hyperkalemia
CS-3150
Observation
Kidney

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Cite this

Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria A randomized, double-blind, placebo-controlled, phase ii trial. / Ito, Sadayoshi; Shikata, Kenichi; Nangaku, Masaomi; Okuda, Yasuyuki; Sawanobori, Tomoko.

In: Clinical Journal of the American Society of Nephrology, Vol. 14, No. 8, 07.08.2019, p. 1161-1172.

Research output: Contribution to journalArticle

@article{87796b305bbf4ccab2948328665b9d0a,
title = "Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria A randomized, double-blind, placebo-controlled, phase ii trial",
abstract = "Background and objectives The progression of kidney disease in some patients with type 2 diabetes mellitus may not be adequately suppressed by renin-angiotensin system inhibitors. Esaxerenone (CS-3150) is a nonsteroidalmineralocorticoid receptor blocker that has shown kidney protective effects in preclinical studies, and it is apotential add-ontherapyto treatdiabetic kidney disease.Thisphase 2 studyevaluatedthe efficacy andsafetyof esaxerenone in Japanese patients with type 2 diabetes mellitus and microalbuminuria. Design, setting, participants, & measurements This multicenter, randomized, double-blind, placebo-controlled trial enrolled 365 hypertensive or normotensive patients with type 2 diabetes mellitus and microalbuminuria (urinary albumin-to-creatinine ratio ≥45 to <300 mg/g creatinine) treated with renin-angiotensin system inhibitor who had eGFR≥30 ml/min per 1.73 m2. Participants were randomized to receive 0.625, 1.25, 2.5, or 5 mg/d esaxerenone or placebo for 12 weeks. The primary end point was the change in urinary albumin-tocreatinine ratio from baseline to week 12 (with last observation carried forward). Results Esaxerenone treatment at 1.25, 2.5, and 5mg/d significantly reduced urinary albumin-to-creatinine ratio by the end of treatment (38{\%}, 50{\%}, and 56{\%}, respectively) compared with placebo (7{\%}; all P<0.001). The urinary albumin-to-creatinine ratio remission rate (defined as urinary albumin-to-creatinine ratio <30mg/g creatinine at the end of treatment and ≥30{\%} decrease from baseline) was 21{\%} in the 2.5- and 5-mg/d groups versus 3{\%} for placebo (both P<0.05). Adverse events occurred slightly more frequently with esaxerenone versus placebo, but the frequencies of drug-related adverse events and discontinuation rates were similar in the placebo and the 0.625-, 1.25-, and 2.5-mg/d groups.Drug-related adverse events and treatment discontinuationsweremarginally higher in the 5-mg/d group. The most common drug-related adverse event was hyperkalemia, which was dose proportional. Conclusions Adding esaxerenone at 1.25, 2.5, and 5 mg/d for 12 weeks to an ongoing renin-angiotensin system inhibitor significantly reduces urinary albumin-to-creatinine ratio in patients with type 2 diabetes mellitus and microalbuminuria.",
author = "Sadayoshi Ito and Kenichi Shikata and Masaomi Nangaku and Yasuyuki Okuda and Tomoko Sawanobori",
year = "2019",
month = "8",
day = "7",
doi = "10.2215/CJN.14751218",
language = "English",
volume = "14",
pages = "1161--1172",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "8",

}

TY - JOUR

T1 - Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria A randomized, double-blind, placebo-controlled, phase ii trial

AU - Ito, Sadayoshi

AU - Shikata, Kenichi

AU - Nangaku, Masaomi

AU - Okuda, Yasuyuki

AU - Sawanobori, Tomoko

PY - 2019/8/7

Y1 - 2019/8/7

N2 - Background and objectives The progression of kidney disease in some patients with type 2 diabetes mellitus may not be adequately suppressed by renin-angiotensin system inhibitors. Esaxerenone (CS-3150) is a nonsteroidalmineralocorticoid receptor blocker that has shown kidney protective effects in preclinical studies, and it is apotential add-ontherapyto treatdiabetic kidney disease.Thisphase 2 studyevaluatedthe efficacy andsafetyof esaxerenone in Japanese patients with type 2 diabetes mellitus and microalbuminuria. Design, setting, participants, & measurements This multicenter, randomized, double-blind, placebo-controlled trial enrolled 365 hypertensive or normotensive patients with type 2 diabetes mellitus and microalbuminuria (urinary albumin-to-creatinine ratio ≥45 to <300 mg/g creatinine) treated with renin-angiotensin system inhibitor who had eGFR≥30 ml/min per 1.73 m2. Participants were randomized to receive 0.625, 1.25, 2.5, or 5 mg/d esaxerenone or placebo for 12 weeks. The primary end point was the change in urinary albumin-tocreatinine ratio from baseline to week 12 (with last observation carried forward). Results Esaxerenone treatment at 1.25, 2.5, and 5mg/d significantly reduced urinary albumin-to-creatinine ratio by the end of treatment (38%, 50%, and 56%, respectively) compared with placebo (7%; all P<0.001). The urinary albumin-to-creatinine ratio remission rate (defined as urinary albumin-to-creatinine ratio <30mg/g creatinine at the end of treatment and ≥30% decrease from baseline) was 21% in the 2.5- and 5-mg/d groups versus 3% for placebo (both P<0.05). Adverse events occurred slightly more frequently with esaxerenone versus placebo, but the frequencies of drug-related adverse events and discontinuation rates were similar in the placebo and the 0.625-, 1.25-, and 2.5-mg/d groups.Drug-related adverse events and treatment discontinuationsweremarginally higher in the 5-mg/d group. The most common drug-related adverse event was hyperkalemia, which was dose proportional. Conclusions Adding esaxerenone at 1.25, 2.5, and 5 mg/d for 12 weeks to an ongoing renin-angiotensin system inhibitor significantly reduces urinary albumin-to-creatinine ratio in patients with type 2 diabetes mellitus and microalbuminuria.

AB - Background and objectives The progression of kidney disease in some patients with type 2 diabetes mellitus may not be adequately suppressed by renin-angiotensin system inhibitors. Esaxerenone (CS-3150) is a nonsteroidalmineralocorticoid receptor blocker that has shown kidney protective effects in preclinical studies, and it is apotential add-ontherapyto treatdiabetic kidney disease.Thisphase 2 studyevaluatedthe efficacy andsafetyof esaxerenone in Japanese patients with type 2 diabetes mellitus and microalbuminuria. Design, setting, participants, & measurements This multicenter, randomized, double-blind, placebo-controlled trial enrolled 365 hypertensive or normotensive patients with type 2 diabetes mellitus and microalbuminuria (urinary albumin-to-creatinine ratio ≥45 to <300 mg/g creatinine) treated with renin-angiotensin system inhibitor who had eGFR≥30 ml/min per 1.73 m2. Participants were randomized to receive 0.625, 1.25, 2.5, or 5 mg/d esaxerenone or placebo for 12 weeks. The primary end point was the change in urinary albumin-tocreatinine ratio from baseline to week 12 (with last observation carried forward). Results Esaxerenone treatment at 1.25, 2.5, and 5mg/d significantly reduced urinary albumin-to-creatinine ratio by the end of treatment (38%, 50%, and 56%, respectively) compared with placebo (7%; all P<0.001). The urinary albumin-to-creatinine ratio remission rate (defined as urinary albumin-to-creatinine ratio <30mg/g creatinine at the end of treatment and ≥30% decrease from baseline) was 21% in the 2.5- and 5-mg/d groups versus 3% for placebo (both P<0.05). Adverse events occurred slightly more frequently with esaxerenone versus placebo, but the frequencies of drug-related adverse events and discontinuation rates were similar in the placebo and the 0.625-, 1.25-, and 2.5-mg/d groups.Drug-related adverse events and treatment discontinuationsweremarginally higher in the 5-mg/d group. The most common drug-related adverse event was hyperkalemia, which was dose proportional. Conclusions Adding esaxerenone at 1.25, 2.5, and 5 mg/d for 12 weeks to an ongoing renin-angiotensin system inhibitor significantly reduces urinary albumin-to-creatinine ratio in patients with type 2 diabetes mellitus and microalbuminuria.

UR - http://www.scopus.com/inward/record.url?scp=85071350179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071350179&partnerID=8YFLogxK

U2 - 10.2215/CJN.14751218

DO - 10.2215/CJN.14751218

M3 - Article

VL - 14

SP - 1161

EP - 1172

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 8

ER -